Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference27 articles.
1. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses;Letko;Nat Microbiol,2020
2. Pathological findings of COVID-19 associated with acute respiratory distress syndrome;Xu;Lancet Respir Med,2020
3. Tumor necrosis factor (TNF) inhibitors;Gerriets,2020
4. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up;Wang;J Infect,2020
5. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV;Liu;J Med Virol,2020
Cited by 468 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Perispinal etanercept stroke trial design: PESTO and beyond;Expert Opinion on Biological Therapy;2024-08-23
2. A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management;Current Topics in Medicinal Chemistry;2024-08
3. Resource Use for COVID-19 Pneumonia in the Accelerating COVID-19 Therapeutic Interventions and Vaccines Trial;CHEST Critical Care;2024-08
4. Predictive value of inflammatory factors and lymphocyte counts in tracheal intubation and death after infection with COVID-19;BMC Pulmonary Medicine;2024-07-29
5. A deep learning drug screening framework for integrating local-global characteristics: A novel attempt for limited data;Heliyon;2024-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3